Piper Sandler analyst Swapnil Malekar raised the firm’s price target on Mirati Therapeutics to $87 from $84 and keeps an Overweight rating on the shares. The company received FDA approval for Krazati with the label language in line with the efficacy seen in the K-1 study, Malekar tells investors in a research note. The analyst views the overall label language to be largely similar to Lumakras and believes that the risk/benefit profile of the two drugs is identical.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MRTX:
- Mirati (NASDAQ:MRTX) Stock Jumps as FDA Approves Lung Cancer Drug
- Mirati Therapeutics: FDA grants accelerated approval for KRAZATI
- Stifel cuts Mirati price target to $73, says move lower ‘overdone’
- Mirati Therapeutics downgraded to Neutral from Buy at Citi (yesterday)
- Mirati Therapeutics price target lowered to $61 from $100 at BofA
